Next Article in Journal
Implementation of WHO Recommended Policies and Interventions on Healthy Diet in the Countries of the Eastern Mediterranean Region: From Policy to Action
Next Article in Special Issue
Serum Vitamins D, B9 and B12 in Greek Patients with Inflammatory Bowel Diseases
Previous Article in Journal
Complementary Feeding in the Preterm Infants: Summary of Available Macronutrient Intakes and Requirements
Previous Article in Special Issue
Probiotic Bacillus Spores Together with Amino Acids and Immunoglobulins Exert Protective Effects on a Rat Model of Ulcerative Colitis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 12
Issue 12
10.3390/nu12123699
nutrients-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

by
Mia Bendix
1,*,
Anders Dige
1,
Søren Peter Jørgensen
1,
Jens Frederik Dahlerup
1,
Bo Martin Bibby
2,
Bent Deleuran
3,4 and
Jørgen Agnholt
1
1
Department of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark
2
Department of Public Health—Department of Biostatistics, Aarhus University, 8000 Aarhus, Denmark
3
Department of Rheumatology, Aarhus University Hospital, 8200 Aarhus, Denmark
4
Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(12), 3699; https://doi.org/10.3390/nu12123699
Received: 5 November 2020 / Revised: 24 November 2020 / Accepted: 26 November 2020 / Published: 30 November 2020
(This article belongs to the Special Issue Nutritional Management for Inflammatory Bowel Diseases)
View Full-Text Download PDF
Browse Figures
Review Reports

Abstract

Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34. View Full-Text
Keywords: vitamin D treatment; Crohn’s disease; infliximab vitamin D treatment; Crohn’s disease; infliximab
►▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Bendix, M.; Dige, A.; Jørgensen, S.P.; Dahlerup, J.F.; Bibby, B.M.; Deleuran, B.; Agnholt, J. Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab. Nutrients 2020, 12, 3699. https://doi.org/10.3390/nu12123699

AMA Style

Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab. Nutrients. 2020; 12(12):3699. https://doi.org/10.3390/nu12123699

Chicago/Turabian Style

Bendix, Mia, Anders Dige, Søren Peter Jørgensen, Jens Frederik Dahlerup, Bo Martin Bibby, Bent Deleuran, and Jørgen Agnholt. 2020. "Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab" Nutrients 12, no. 12: 3699. https://doi.org/10.3390/nu12123699

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop